PGT-A & Embryo Genetic Testing in Thailand
Preimplantation genetic testing can add another decision layer to IVF: which embryos are biopsied, what the laboratory is testing, what a result can and cannot tell you, and how those results change the transfer plan.
For international patients considering PGT-A in Thailand, the useful comparison is not simply the advertised genetic-testing fee. It is the complete pathway from IVF and blastocyst culture through biopsy, vitrification, genetic analysis, counselling, storage and the later frozen embryo transfer.
What does PGT-A actually test?
PGT-A stands for preimplantation genetic testing for aneuploidy. In broad terms, the laboratory analyses cells taken from an embryo to look for abnormalities in chromosome number. The test is performed as part of IVF; it is not a standalone fertility test and it does not directly measure whether an embryo will implant, produce an ongoing pregnancy or result in a healthy baby.
The distinction matters. A result can help a fertility specialist prioritise embryos for transfer in some circumstances, but it cannot turn a poor-prognosis embryo into a good one, create more embryos, reverse age-related decline in egg quality or eliminate every genetic and pregnancy risk.
Patients also encounter other forms of preimplantation genetic testing. PGT-M may be used where there is a known single-gene condition in a family, while PGT-SR relates to certain structural chromosome rearrangements. Those are different clinical questions from routine discussion of PGT-A, and they require appropriate genetics input and a laboratory capable of the specific testing required.
Separate the clinical reason, the laboratory process and the result
Why test?
Ask what specific problem PGT-A is intended to solve in your case. Age, reproductive history, embryo number and previous treatment can affect the discussion. A test should have a purpose, not simply be an automatic IVF add-on.
How is it done?
Biopsy technique, embryo culture, vitrification, sample identification and the genetics laboratory all form part of the pathway. The quality of coordination matters as much as the test label.
What happens next?
A report needs interpretation. Ask how euploid, aneuploid, mosaic, inconclusive or no-result findings are handled and how the clinic approaches re-biopsy or transfer decisions where uncertainty remains.
The decision is individual, not a universal IVF rule
PGT-A is often discussed with patients of advanced maternal age, those with repeated IVF treatment, recurrent pregnancy loss, or patients who have several blastocysts and want to understand whether chromosome screening could help prioritise transfer. But those broad categories do not mean every patient within them will benefit in the same way.
A key question is how many embryos are realistically expected. If a cycle produces very few blastocysts, testing may leave a patient with no embryo classified for transfer, while the evidence supporting routine PGT-A for all IVF patients is not the same as evidence for carefully selected situations. Your specialist should explain the expected advantage, limitations and alternatives in language you can understand.
For patients travelling to Thailand, this discussion is particularly important before flights are booked. The treatment plan may involve stimulation and retrieval in Thailand, biopsy and freezing, then a later return for frozen embryo transfer after results are available.
Compare the provider, fertility specialist and complete PGT pathway together
A low headline genetic-testing price tells you very little if it excludes embryo biopsy, IVF/ICSI, blastocyst culture, vitrification, genetics-laboratory fees, storage or the later frozen embryo transfer. JLIT brings those moving parts into one enquiry so you can compare like with like.
Ask for the quotation in layers
Five stages from IVF planning to embryo transfer
PGT-A changes the rhythm of an IVF cycle because the genetic result normally sits between embryo creation and transfer. Understanding that sequence helps international patients plan time in Thailand and avoid assuming that retrieval and transfer will happen in the same visit.
Plan
Review fertility history, age, ovarian reserve, semen results, previous pregnancies or losses, and the reason PGT-A is being considered.
Create
Complete ovarian stimulation, egg retrieval, fertilisation and embryo culture. The number of eggs is not the same as the number of blastocysts available for biopsy.
Biopsy
Suitable embryos are biopsied by the embryology team and the samples are identified for genetic analysis.
Freeze & test
Embryos are vitrified while the laboratory processes the biopsy samples and produces a report.
Review & transfer
The fertility specialist interprets the results with you and plans a later frozen embryo transfer when appropriate.
“Normal” and “abnormal” are not the only possible outcomes
Patients often expect PGT-A to produce a simple yes-or-no answer. Reports can be more complicated. A sample may be reported as euploid, meaning the tested cells show the expected chromosome complement; aneuploid, where an abnormal chromosome number is detected; mosaic, where the sample suggests a mixture of cell lines; or occasionally inconclusive/no-result.
The terminology, thresholds and reporting practices can vary between laboratories. Mosaic findings in particular need careful counselling because the implications are not identical for every result. Decisions about transfer should be made with the treating fertility team and, where appropriate, genetics professionals rather than by reading a laboratory label in isolation.
Build your Thailand trip around your treatment.
Treatment in Thailand often means several appointments, with free days or recovery time in between. Plan where you stay, how you spend those days and when you fly — then send it to JLIT alongside your treatment enquiry.
- Choose your city and dates around your appointments
- Explore accommodation close to your clinic or hospital
- Free, no-obligation — no booking or payment
Plan the treatment trip around the biology, not the flight schedule
An IVF cycle is driven by ovarian response and embryo development. Monitoring dates can move, retrieval timing depends on follicular development, and not every fertilised egg becomes a blastocyst suitable for biopsy. Build flexibility into travel rather than booking a rigid departure immediately after a predicted date.
Some international patients complete preliminary blood tests, semen analysis or scans at home and send the records to the Thai clinic before travelling. Others prefer to complete the full assessment in Thailand. Either approach needs agreement with the treating team because laboratories use different units, reference ranges and protocols.
After retrieval, many patients can return home while embryos are cultured, biopsied, frozen and tested, then return to Thailand later for FET. Ask when the clinic expects results, how the consultation will be conducted, how long embryos will be stored before transfer and what preparation can be completed in your home country.
JLIT's role is to bring the medical and practical sides together: clinic and specialist comparison, current quotations, accommodation, flights, airport transfers, local transport and the timing of a later transfer visit.
20 questions to put in writing
The best protection against confusing package comparisons is a written checklist. Ask the clinic to answer the points that apply to your case before you pay a deposit or arrange international travel.
Chromosome screening is not a complete genetic guarantee
PGT-A focuses on chromosome number in the sampled cells. It does not screen for every genetic condition, every birth defect, every cause of miscarriage or every factor that affects implantation. Even after embryo testing, pregnancy care and appropriate prenatal screening or diagnostic discussions may still be recommended.
Embryo biopsy also samples cells that will contribute to placental tissue rather than examining every cell of the embryo. That is one reason results, particularly mosaic findings, need interpretation rather than being treated as absolute labels. Ask what confirmatory prenatal options the clinic recommends if pregnancy occurs.
PGT-M and PGT-SR are different tests used for specific inherited or structural chromosome indications. If you or your partner has a known genetic condition, balanced translocation or significant family history, tell the clinic before the IVF cycle begins because test development and counselling may need to happen in advance.
Compare the complete cycle, not the PGT line item
The total cost of PGT-A treatment in Thailand can be spread across several invoices. IVF or ICSI, medicines, monitoring, egg retrieval, anaesthesia, embryo culture, biopsy, genetic testing, freezing, storage and the later frozen embryo transfer may all be priced separately. The number of embryos tested can also change the genetic-laboratory fee.
A clinic may advertise a package that appears lower because it includes only a fixed number of embryos or excludes medication and FET. Another may quote a higher figure that covers more of the pathway. Neither can be compared fairly until the inclusions are aligned.
The fertility clinic and the genetics pathway need to work as one system
For PGT-A, clinic selection should include more than the name of the fertility specialist. Ask how the embryology laboratory performs biopsy, how samples are identified and transferred to the genetics laboratory, what happens when a report is delayed or inconclusive, and who counsels you on the result.
Experience matters at several hand-offs: stimulation and retrieval, fertilisation, blastocyst culture, biopsy, vitrification, genetic analysis, storage, warming and transfer. A polished consultation is useful, but the quality of the pathway depends on the team behind it.
JLIT can help you compare the treatment route, provider, fertility specialist and available pricing in one place. Where a published price exists, use it as a starting point; where the case needs an individual quotation, request the complete current figure rather than relying on an old package headline.
The value of testing depends partly on what reaches the laboratory
One of the easiest mistakes when researching PGT-A in Thailand is to start with the genetic test and work backwards. In practice, the pathway starts much earlier with ovarian response, egg maturity, fertilisation and embryo development. A patient may retrieve several eggs but have fewer mature eggs, fewer normally fertilised embryos and fewer blastocysts suitable for biopsy. The number actually tested can therefore be much smaller than the number discussed at the beginning of stimulation.
Age matters because chromosome abnormalities in embryos become more common as egg age increases, but age alone does not tell a clinic how many blastocysts a particular patient will produce. AMH and antral follicle count can help estimate ovarian response, yet they do not directly measure embryo chromosome status. Previous IVF cycles can sometimes provide more personalised information: how many eggs were mature, how fertilisation progressed and how many embryos reached blastocyst.
That is why a useful consultation should include realistic attrition at each stage. Ask the specialist to explain the range of outcomes rather than quoting a single expected embryo number. If only one embryo reaches biopsy, the financial and clinical trade-offs can feel very different from a cycle producing six or eight blastocysts. The decision to test should still make sense if the cycle performs below the optimistic scenario.
For patients over 40, the discussion often becomes particularly important because both embryo number and chromosome status may affect the chance of having an embryo available for transfer. PGT-A can provide information about tested embryos, but it cannot compensate for a low number of eggs or embryos. Some patients may need to consider whether embryo accumulation across more than one retrieval is part of the strategy, and how that changes cost, storage and travel.
Make sure the test name matches the genetic question
“Embryo genetic testing” is often used as a catch-all phrase, but different tests answer different questions. This is more than terminology: the laboratory preparation, counselling, family records and timing can change depending on the indication.
PGT-A
PGT-A screens embryos for chromosome-number abnormalities. It is usually discussed as part of embryo selection in IVF and does not target one known inherited single-gene disorder.
PGT-M
PGT-M is designed for a known monogenic, or single-gene, condition. The genetics laboratory may need information from the couple and sometimes relatives before the IVF cycle, and test preparation can take time.
PGT-SR
PGT-SR is used in relation to certain structural chromosome rearrangements, such as a known balanced translocation in a parent. The genetics question and reporting pathway differ from routine PGT-A.
If a family history includes a known genetic diagnosis, repeated affected pregnancies, a chromosome rearrangement or an unexplained pattern that has raised concern, tell the clinic before stimulation begins. A standard PGT-A package may not answer the relevant question. The correct first step may be genetics review rather than simply adding a test at blastocyst stage.
Plan for the difficult report before you receive it
A straightforward euploid or aneuploid report is easier to understand than a mosaic or inconclusive finding. Mosaic reporting reflects a mixture of chromosome signals in the sampled cells. The clinical implications depend on the chromosomes involved, the level and type of mosaicism reported, the laboratory methodology and current professional guidance. It is not a result that should be reduced to “good” or “bad” without counselling.
Before treatment, ask whether the clinic transfers embryos reported as mosaic in any circumstances, who provides counselling, and whether the genetics laboratory offers direct consultation. If no euploid embryo is available, patients should not be forced to discover the clinic's policy for the first time while emotionally processing a complex report.
An inconclusive or no-result sample creates another decision. Re-biopsy may sometimes be discussed, but it means warming the embryo, taking another sample and re-vitrifying it, with additional handling and potentially additional cost. The right response depends on the embryo, the original result, laboratory practice and the patient's alternatives. Ask what the clinic normally does and whether a second genetics fee applies.
International patients should also know how counselling happens after they have flown home. Confirm whether the specialist will review the report by video, whether a genetics counsellor is available remotely, and how quickly the clinic can provide the written report. Good communication matters because the next travel decision may depend on that conversation.
Be careful when a clinic turns PGT-A into a marketing promise
Fertility marketing can make embryo testing sound as though it automatically increases the chance of having a baby. The reality is more nuanced. PGT-A can change which embryo is selected for transfer and may reduce some transfers of embryos with chromosome abnormalities, but the effect on outcomes depends on the patient population, embryo availability and the outcome being measured.
When a provider quotes a “success rate,” ask for the denominator. Is it per embryo transfer, per retrieval, per patient who had at least one euploid embryo, or per treatment cycle started? A high success rate per transfer can exclude patients who never obtained an embryo classified for transfer. That may be useful information about transfer performance, but it is not the same as the chance that a new patient starting IVF will take home a baby.
Also ask whether the statistic is clinic-specific, laboratory-specific or taken from a broader publication. Age groups should be separated where possible. Results from patients using donor eggs should not be blended into a figure presented to someone using their own eggs at 42. A useful provider should be willing to explain what its numbers include rather than relying on a headline percentage.
JLIT's comparison pathway is designed around this principle: provider, specialist, price and treatment details should be considered together. A clinic is not automatically better because it advertises a higher percentage, and a cheaper package is not automatically better if it excludes the laboratory stages that matter.
The report is a bridge to the next treatment decision
If a euploid embryo is available
The next step is usually planning a frozen embryo transfer. That still requires endometrial preparation, timing, embryo warming and transfer. A euploid result does not remove uterine, medical or embryo-related factors that can affect implantation.
If no euploid embryo is available
The specialist should review the complete cycle: ovarian response, fertilisation, embryo development, age and the actual genetic results. Options may include another retrieval, a revised stimulation strategy, further counselling or other family-building pathways.
If the report is uncertain
Mosaic or inconclusive findings need a specific discussion rather than an automatic decision. Ask what professional guidance the clinic follows and whether genetics counselling is available before deciding what to do.
For an international patient, this is also the point to decide whether the next step should happen in Thailand and when. If an FET is planned, obtain the medication and monitoring schedule before booking the return trip. If another retrieval is being considered, request a revised quotation and ask what the team learned from the first cycle.
Questions patients commonly ask before embryo genetic testing
What is PGT-A?
PGT-A is preimplantation genetic testing for aneuploidy. It analyses cells biopsied from an IVF embryo to screen chromosome number. It is one part of an IVF pathway and does not guarantee implantation, pregnancy or a healthy baby.
Do I need IVF to have PGT-A?
Yes. Embryos must first be created through IVF or ICSI, cultured to an appropriate stage and biopsied. PGT-A is not a blood test that can be performed without IVF.
Does PGT-A improve IVF success rates?
The answer depends on the patient group and the outcome being measured. PGT-A may help prioritise embryos for transfer in selected situations, but it does not create more embryos or improve their underlying chromosome status. Ask your specialist what benefit is expected in your individual case.
Who should consider PGT-A?
It may be discussed in situations such as advanced maternal age, previous IVF treatment, recurrent pregnancy loss or where several blastocysts are available, but suitability is individual. It should not be treated as mandatory for every IVF patient.
What is an embryo biopsy?
An embryologist removes a small number of cells from a suitable embryo for testing. The embryo is commonly vitrified while the biopsy sample is analysed.
Does biopsy harm the embryo?
Biopsy is a skilled laboratory procedure and no intervention is risk-free. Ask the clinic about its biopsy experience, embryo survival after warming and how laboratory performance is monitored.
What does euploid mean?
Euploid generally means the tested sample shows the expected chromosome number. It does not mean the embryo is guaranteed to implant or that every possible genetic condition has been excluded.
What does aneuploid mean?
Aneuploid means the tested sample shows an abnormal chromosome number. The treating team should explain the specific result and the clinic’s policy for counselling and management.
What is a mosaic embryo result?
A mosaic result suggests more than one chromosome pattern in the sampled cells. Interpretation can be complex and may depend on the laboratory report and professional guidance. It deserves specialist/genetics counselling rather than a simple internet interpretation.
Can PGT-A tell me the sex of an embryo?
Chromosome testing may reveal sex chromosomes, but what information is reported or how it may legally or ethically be used depends on local rules, clinic policy and the medical indication. Do not assume non-medical sex selection is available.
Is PGT-A the same as PGT-M?
No. PGT-M is designed around a known single-gene condition, while PGT-A screens chromosome number. PGT-SR addresses certain structural chromosome rearrangements. The preparation and counselling can differ.
How long do PGT-A results take?
Turnaround depends on the genetics laboratory and the case. Ask for the current expected timeframe before travel because results can affect when a frozen embryo transfer can be planned.
Why are embryos frozen after biopsy?
Freezing allows the embryo to be stored safely while genetic analysis is completed and gives time to plan a later endometrial-preparation and frozen-transfer cycle.
Can I transfer an embryo in the same IVF cycle?
PGT pathways commonly involve a later frozen embryo transfer because embryos are biopsied and vitrified while results are processed. Confirm the exact plan with your clinic.
What if all embryos test abnormal?
There may be no embryo recommended for transfer from that cohort. The specialist should discuss the report, whether any result needs further counselling, and the realistic options for another cycle or alternative treatment.
What if the test gives no result?
An inconclusive or no-result sample can occur. Ask before treatment whether re-biopsy may be considered, what risks and costs are involved, and how the clinic approaches the decision.
How much does PGT-A cost in Thailand?
Costs vary by clinic, laboratory and number of embryos tested. Compare the complete IVF, biopsy, testing, vitrification, storage and later FET pathway rather than a single PGT-A fee.
How many trips to Thailand will I need?
Many international patients have one visit for stimulation and retrieval and a later visit for frozen embryo transfer. Some preliminary monitoring or FET preparation may be possible at home if agreed with the Thai clinic.
Do I still need prenatal testing after PGT-A?
PGT-A is not a substitute for all prenatal screening or diagnostic options. If pregnancy occurs, discuss appropriate pregnancy testing with your obstetric team.
Can JLIT help compare clinics, doctors and prices?
Yes. JLIT can bring the provider, fertility specialist, available published or current pricing and Thailand travel requirements into one enquiry so you can compare the complete pathway rather than isolated package headlines.
Choose PGT-A because it changes a decision — not because it is another box on an IVF package.
The strongest plan connects the clinical reason for testing with an experienced embryology pathway, clear genetics interpretation, a complete written quotation and a realistic Thailand itinerary. JLIT can help you compare those pieces before you commit.
